Our mission

Precigen’s mission is to discover, develop and commercialize next generation gene and cell therapies focused in immuno-oncology, autoimmune disorders, and infectious diseases.

Precigen Subsidiaries

Precigen’s healthcare assets include wholly-owned subsidiaries PGEN Therapeutics, ActoBio Therapeutics and Exemplar Genetics, and a majority ownership interest in Triple-Gene. While our primary focus is in healthcare, Precigen controls two non-healthcare businesses: an industry-leading methane bioconversion business, MBP Titan, LLC, and an established bovine genetics company, Trans Ova Genetics.